Spectrophotometric Determination of Cisplatin Using Derivatizing Agent

DOI:

https://doi.org/10.37285/ijpsn.2023.16.3.4

Authors

  • Dipali Talele Department of Pharmaceutics, Faculty of Pharmacy, Parul Institute of Pharmacy and Research, Parul University,
  • Deepa Patel Department of Pharmaceutics, Faculty of Pharmacy, Parul Institute of Pharmacy and Research, Parul University,

Abstract

Background: Cisplatin is an anti-neoplastic agent used to treat cancer. In the U.V. range, Cisplatin has quite a low molar absorptivity. Hence, a Derivatization reaction is required for the spectrometric determination in the pharmaceutical dosage form.

Objective: This paper aims to exemplify detail about the spectrophotometric study of Cisplatin using Derivatizing agent. 

Method: Cisplatin has been estimated by Complexation with ortho-phenylene diamine at wavelength 705 nanometers.

Results: The calibration curve was linear with a regression coefficient value of 0.999 in the concentration range of 0.5- 3.5 μg/ml. The technique was validated by determining different parameters and found to be satisfactory.

Conclusion: The technique was efficiently helpful for the estimation of Cisplatin.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Cisplatin, Derivatization, o-phenylene diamine, U.V. spectrometry, Complexation and ligand exchange complex., Cisplatin, Derivatization, o-phenylene diamine, U.V. spectrometry, ligand exchange complex, Complexation

Downloads

Published

2023-05-31

How to Cite

1.
Talele D, Patel D. Spectrophotometric Determination of Cisplatin Using Derivatizing Agent. Scopus Indexed [Internet]. 2023 May 31 [cited 2024 May 20];16(3):6504-11. Available from: https://ijpsnonline.com/index.php/ijpsn/article/view/3851

Issue

Section

Research Articles

References

Marselos M, Vainio H. Carcinogenic properties of pharmaceutical agents evaluated in the IARC Monographs programme. Carcinogenesis. 1991 Oct 1;12(10):1751-66.
Wong E, Giandomenico CM. Current status of platinum-based antitumor drugs. Chemical reviews. 1999 Sep 8;99(9):2451-66.
Rosenberg B, Van Camp L, Grimley EB, Thomson AJ. The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum (IV) complexes. Journal of Biological Chemistry. 1967 Mar 25;242(6):1347-52.
Bosch ME, Sánchez AR, Rojas FS, Ojeda CB. Analytical methodologies for the determination of Cisplatin. Journal of pharmaceutical and biomedical analysis. 2008 Jul 15;47(3):451-9.
Khuhawar MY, Arain GM, Shah A. Spectrophotometry determination of platinum (II) from platinum based cisplatin and carboplatin anticancer injections. The Nucleus. 2004;41(1-4):59-62.
Inagaki K, Yonehara S, Kidani Y. Direct determination of cis-dichlorodiammineplatinum (II) in urine by derivative spectroscopy. Chemical and Pharmaceutical Bulletin. 1985 Aug 25;33(8):3369-74.
Golla ED, Ayres GH. Spectrophotometric determination of platinum with o-phenylenediamine. Talanta. 1973 Feb 1;20(2):199-210.
Baumann RA, Gooijer C, Velthorst NH, Frei RW, Klein I, Van der Vijgh WJ. Quantitative determination of Cisplatin in body fluids by liquid chromatography with quenched phosphorescence detection. Journal of pharmaceutical and biomedical analysis. 1987 Jan 1;5(2):165-70.
Raghavan R, Burchett M, Loffredo D, Mulligan JA. Low-level (PPB) determination of Cisplatin in cleaning validation (Rinse Water) Samples. II. A high-performance liquid chromatogrphic method. Drug development and industrial pharmacy. 2000 Jan 1;26(4):429-40.
Lanjwani SN, Zhu R, Khuhawar MY, Ding Z. High performance liquid chromatographic determination of platinum in blood and urine samples of cancer patients after administration of cisplatin drug using solvent extraction and N, N′-bis (salicylidene)-1, 2-propanediamine as complexation reagent. Journal of pharmaceutical and biomedical analysis. 2006 Mar 3;40(4):833-9.
Khuhawar MY, Arain GM. Liquid chromatographic determination of cis-platin as platinum (II) in pharmaceutical preparation, serum and urine samples of cancer patients. Talanta. 2005 Mar 31;66(1):34-9.
Petrlova J, Potesil D, Zehnalek J, Sures B, Adam V, Trnkova L, Kizek R. Cisplatin electrochemical biosensor. Electrochimica acta. 2006 Jul 15;51(24):5169-73.
Anilanmert B, Yalçin G, Ariöz F, Dölen E. The spectrophotometric determination of Cisplatin in urine, using o-phenylenediamine as derivatising agent. Analytical letters. 2001 Jan 31;34(1):113-23.
Riley CM, Sternson LA. Cisplatin. InAnalytical profiles of drug substances 1985 Jan 1 (Vol. 14, pp. 77-105). Academic Press.
Heckelman PE, Kinneary JF, O'Neil MJ, Smith A. The Merck index: an encyclopedia of chemicals, drugs, and biologicals. 1996.
Martindale WH. The Extra Pharmacopoeia, vol. 1. The Extra Pharmacopoeia, Vol. 1. 1936(Edn 21).
Hasson H, Warshawsky A. High-performance liquid chromatographic determination of cis-diamminedichloroplatinum (II)(Cisplatin) as the o-phenylenediamine complex. Journal of Chromatography B: Biomedical Sciences and Applications. 1990 Aug 1;530:219-21.
Basotra M, Singh SK, Gulati M. Development and validation of a simple and sensitive spectrometric method for estimation of cisplatin hydrochloride in tablet dosage forms: application to dissolution studies. International Scholarly Research Notices. 2013;2013.